Pharmacogenomics (PGx)
- Home
- Applications
- Research areas
- Pharmacogenomics (PGx)
We conclude that PGx based on targeted [Oxford Nanopore sequencing] is a valuable tool to advance the implementation of personalised medicine
Deserranno, K. et al. Front. Pharmacol. (2023)
- Access full-gene, long-read coverage results to unambiguously phase haplotypes for PGx star allele and variant calling
- Call all PGx variants, including small and structural variants, and complex copy number alterations
- Achieve high-confidence, comprehensive PGx sequencing at your choice of throughput
Comprehensively characterise PGx gene variants in a single assay
Pharmacogenomics (PGx) is the study of how genomics influences drug responses with the aim of identifying precise drug treatments for individuals. Genomic variation influences how drugs are absorbed, distributed, and metabolised (pharmacokinetics), as well as how they interact with biological pathways (pharmacodynamics). Furthermore, genetic differences can contribute to adverse drug reactions, such as hypersensitivity and allergic reactions, highlighting the need for personalised drug dosing based on genetics to improve treatment outcomes.
A major challenge of PGx is the complexity and diversity of genomic variations, which cannot be characterised on one platform using traditional methods. Oxford Nanopore Technologies offers a complete PGx solution, enabling comprehensive analysis all PGx variations in a single assay.
)
Featured content
Publication
A nanopore sequencing-based pharmacogenomic panel to personalise tuberculosis drug dosing
Publication
Genetic variants, haplotype determination, and function of novel alleles of CYP2B6 in a Han Chinese population